Activation of the nuclear factor-B pathway by Epstein-Barr virus-encoded latent membrane protein-1 (LMP-1) leads to an up-regulation of the major histocompatibility complex class I antigen-processing pathway. Paradoxically, LMP-1 itself induces a subdominant CD8 ؉ T-cell response and appears to have evolved to avoid immune recognition. Here we show that, although expression of LMP-1 in human cells dramatically enhanced the trans-presentation of CD8 ؉ T-cell epitopes, cis-presentation of LMP-1-derived epitopes was severely impaired. Testing of a series of LMP-1 mutants revealed that deletion of the first transmembrane domain of LMP-1, which prevented self-aggregation, significantly enhanced cis-presentation of T-cell epitopes from this protein, whereas it lost its ability to up-regulate trans-presentation.
Introduction
The specificity of interaction between T cells and antigenpresenting cells is determined by 2 distinct components, namely, major histocompatibility complex (MHC)-restricted presentation of a peptide epitope and a heterodimeric ␣␤ cell-surface protein called the T-cell receptor. Viruses that establish persistent infection or are associated with malignant transformation have evolved unique mechanisms to interfere with this interaction to evade antiviral T-cell responses. 1, 2 These escape mechanisms include down-regulation of antigen processing, limiting expression of immunodominant viral proteins, viral replication in immuneprivileged tissues, and genetic variation affecting peptide binding to MHC class I or recognition by the T cells. [3] [4] [5] Epstein-Barr virus (EBV) exploits many immune evasive strategies to successfully establish a latent infection in B cells. 6 Analysis of the role of individual EBV latent antigens in the regulation of antigenprocessing genes indicated that latent membrane protein-1 (LMP-1) was sufficient to up-regulate expression of transporters associated with antigen processing and trans-presentation of MHC class I-restricted epitopes in B cells. 3 Subsequent studies demonstrated that the immunomodulatory effects of LMP-1 are mediated through C-terminal activator regions (CTAR1 and CTAR2), 7 which are involved in the induction of the nuclear factor-B (NF-B) family protein Rel-B. 8 Paradoxically, CD8 ϩ T-cell responses to LMP-1 are generally very low and rarely detected in healthy virus carriers, suggesting that LMP-1 may limit its cis-presentation through the MHC class I pathway. 9, 10 We have delineated a mechanism by which LMP-1 limits its self-presentation without compromising its ability to modulate trans-presentation of CD8 ϩ T-cell epitopes.
Fluorescence microscopy
C33A cells were transfected with LMP-1 expression vectors, fixed and stained with DAPI and phalloidin, and analyzed using a DeltaVision Core DV (Applied Precision, Issaquah, WA).
Results and discussion
To assess the impact of LMP-1 expression on cis-and transpresentation of MHC class I-restricted epitopes, BJAB-MTLM6 (LMP-1 ϩ ) and BJAB-gpt (LMP-1 Ϫ ) cells, which display a marked difference in surface MHC expression ( Figure 1A ), were infected with recombinant vaccinia virus encoding the EBNA-3 or the HCMV-encoded, pp65, and then incubated with CD8 ϩ T cells specific for EBNA-3, pp65, or LMP-1. As previously reported, 3 a 2-to 3-fold higher stimulation of EBNA-3 and pp65-specific T cells was observed when exposed to BJAB.MTLM6 cells compared with BJAB-gpt cells ( Figure 1B) . In contrast, activation of T cells specific for an human leukocyte antigen (HLA) A2-restricted LMP-1 epitope (YLQQNWWTL), 9,10 after incubation with BJAB-MTLM6 cells, was only evident after presensitization of these cells with peptide ( Figure 1C ). It is important to stress here that poor endogenous recognition of LMP-1 was not the result of low avidity of LMP-1-specific T cells (data not shown). 
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To extend these investigations, we included multiple LMP-1 sequences from both healthy persons and nasopharyngeal carcinoma (NPC) patients in our analysis. Data presented in Figure  1D show that, although all LMP-1 variants up-regulated the expression of MHC class I on a human epithelial cell line, C33A, considerable activation of LMP-1-specific T cells was only evident after incubation with peptide-sensitized cells ( Figure 1E ). In contrast, LMP-1 expression in C33A cells enhanced trans-presentation of CD8 ϩ T-cell epitopes from another EBV-encoded membrane protein, LMP-2A ( Figure 1F ). Collectively, these results suggested that, despite its capacity to up-regulate trans-presentation via the MHC class I pathway, LMP-1 limits its self-presentation to CD8 ϩ T cells.
Much of the data presented in Figure 1A through F are based on either stable or transient expression of LMP-1. To confirm these observations, we assessed endogenous presentation of LMP-1 epitopes in EBV-transformed LCLs. Data presented in Figure 1G show that, although activation of LMP-2A specific T cells was evident after incubation with HLA-matched LCLs, very low levels of activation of T cells specific for multiple LMP-1-encoded peptide epitopes was observed. Activation of LMP-1-specific T cells could be detected after incubation with peptide-sensitized LCLs (data not shown).
To investigate the mechanism for this immune evasion, we tested a series of LMP-1 expression vectors with mutations in the CTAR1 and/or CTAR2 domain; and a deletion mutant commencing at the second methionine of LMP-1 (⌬1-43LMP-1-GFP), which removes the first trans-membrane domain ( Figure  2A ). This domain has been shown to have immunomodulatory effect, 21 and ⌬1-43LMP-1 has been used for expanding LMP-1-specific T cells. 22 Although mutations within the CTAR domains had no impact on the presentation of LMP-1 epitopes, deletion of the first trans-membrane domain enhanced endogenous presentation of HLA class I-restricted epitopes ( Figure 2B ). Interestingly, deletion of the first trans-membrane domain of LMP-1 completely impaired its ability to enhance MHC class I expression (data not shown). Consistent with previous studies, 17 intracellular localization analysis using fluorescent microscopy revealed that, although full-length LMP-1 and its CTAR mutants formed large aggregates in the perinuclear region, ⌬1-43LMP-1-GFP lost its ability to aggregate ( Figure 2C) . Subsequent experiments confirmed the data presented in Figure 2A through C, whereby presentation of LMP-1 epitopes 9,10 was enhanced in HEK293 and C666.1 cells after expression of ⌬1-43LMP-1-GFP ( Figure 2D ). This enhanced presentation was not the result of increased expression of ⌬1-43LMP-1-GFP compared with full-length LMP-1 ( Figure 2E ). These observations indicate that, although the NF-B signaling domains had no impact on cis-presentation of LMP-1 epitopes, aggregation of this protein (a critical requirement for trans-presentation) limits its accessibility to the MHC class I processing machinery. We next assessed the potential role of peptide transporters (TAP1 and TAP2) and immunoproteasomes in the endogenous processing of CD8 ϩ T-cell epitopes from LMP-1. Data presented in Figure 2F show that TAP1 and TAP2 and immunoproteasomedeficient T2 cells were twice as efficient in activating LMP-1-specific T cells compared with the parental T1 cell line. Further analysis revealed that inhibition of TAP1 and TAP2 function in LCL, using HSV-encoded ICP47, had minimal impact on the presentation of LMP-1 epitopes (data not shown). However, pretreatment of cells expressing wtLMP-1 and ⌬1-43LMP-1 with proteasomal inhibitors (particularly MG132) significantly enhanced the endogenous presentation of CD8 ϩ T-cell epitopes from this protein ( Figure 2G ). These observations are consistent with previous studies on LMP and influenza nucleoprotein, where proteasome-inhibitor treatment enhanced endogenous presentation of CD8 ϩ T-cell epitopes. [23] [24] [25] In conclusion, data presented in this study indicate that, in addition to constraining its cis-presentation through aggregation, epitopes encoded within LMP-1 protein are most probably destroyed by cellular proteasomes, providing a dual strategy by which LMP-1 limits self-presentation to CD8 ϩ T cells. To our knowledge, this is the first documented evidence of any pathogen-encoded protein that can activate the antigen-processing machinery of the cell while successfully evading a highly efficient scanning process by the components of this machinery for foreign protein.
